BR112018009725A8 - compostos de cefém, sua produção e uso - Google Patents
compostos de cefém, sua produção e usoInfo
- Publication number
- BR112018009725A8 BR112018009725A8 BR112018009725A BR112018009725A BR112018009725A8 BR 112018009725 A8 BR112018009725 A8 BR 112018009725A8 BR 112018009725 A BR112018009725 A BR 112018009725A BR 112018009725 A BR112018009725 A BR 112018009725A BR 112018009725 A8 BR112018009725 A8 BR 112018009725A8
- Authority
- BR
- Brazil
- Prior art keywords
- unsubstituted
- substituted
- spacer
- atom
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/48—Methylene radicals, substituted by hetero rings
- C07D501/56—Methylene radicals, substituted by hetero rings with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/04—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265625P | 2015-12-10 | 2015-12-10 | |
| US62/265,625 | 2015-12-10 | ||
| PCT/CA2016/051428 WO2017096472A1 (en) | 2015-12-10 | 2016-12-05 | Cephem compounds, their production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018009725A2 BR112018009725A2 (en) | 2018-11-06 |
| BR112018009725A8 true BR112018009725A8 (pt) | 2019-02-26 |
Family
ID=59012429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018009725A BR112018009725A8 (pt) | 2015-12-10 | 2016-12-05 | compostos de cefém, sua produção e uso |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9751894B2 (https=) |
| EP (1) | EP3386977A4 (https=) |
| JP (1) | JP6967000B2 (https=) |
| KR (2) | KR102135230B1 (https=) |
| CN (1) | CN108463461B (https=) |
| AU (1) | AU2016367284C1 (https=) |
| BR (1) | BR112018009725A8 (https=) |
| CA (1) | CA3005779C (https=) |
| EA (1) | EA039648B1 (https=) |
| HK (1) | HK1254209A1 (https=) |
| IL (1) | IL259234B (https=) |
| WO (1) | WO2017096472A1 (https=) |
| ZA (1) | ZA201802654B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096472A1 (en) | 2015-12-10 | 2017-06-15 | Naeja-Rgm Pharmaceuticals Inc. | Cephem compounds, their production and use |
| KR20200091395A (ko) * | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법 |
| TWI795549B (zh) * | 2018-04-06 | 2023-03-11 | 日商富士軟片股份有限公司 | 新穎青黴烷衍生物或其鹽、醫藥組成物及其應用 |
| KR102484880B1 (ko) | 2018-06-08 | 2023-01-05 | 엘지디스플레이 주식회사 | 신축 가능한 표시장치, 패널 구동회로 및 구동방법 |
| US11905286B2 (en) | 2018-08-09 | 2024-02-20 | Antabio Sas | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| EP3833665B1 (en) | 2018-08-09 | 2023-07-19 | Antabio SAS | Diazabicyclooctanones as inhibitors of serine beta-lactamases |
| US12257307B2 (en) | 2019-06-24 | 2025-03-25 | Diverse Biotech, Inc. | β-lactam-cannabinoid conjugate molecules |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3118732A1 (de) * | 1981-05-12 | 1982-12-02 | Hoechst Ag, 6000 Frankfurt | Cephalosporinderivate und verfahren zu ihrer herstellung |
| US4406899A (en) * | 1982-03-04 | 1983-09-27 | Bristol-Myers Company | Cephalosporins |
| IL77458A (en) * | 1985-01-14 | 1990-07-26 | Eisai Co Ltd | Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor |
| ATE89826T1 (de) * | 1985-03-01 | 1993-06-15 | Takeda Chemical Industries Ltd | Antibakterielle verbindungen, ihre herstellung und verwendung. |
| US4910301A (en) * | 1985-08-05 | 1990-03-20 | Bristol-Myers Company | Cefepime cephalosporin salts |
| US4777128A (en) | 1986-05-27 | 1988-10-11 | Ethigen Corporation | Fluorescence immunoassay involving energy transfer between two fluorophores |
| US5173485A (en) * | 1988-03-09 | 1992-12-22 | Fujisawa Pharmaceutical Company, Ltd. | Cephem compounds |
| GB8805642D0 (en) | 1988-03-09 | 1988-04-07 | Fujisawa Pharmaceutical Co | New cephem compounds & processes for preparation thereof |
| US5215982A (en) | 1989-11-10 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
| CA2216259A1 (en) | 1996-09-25 | 1998-03-25 | Eisai Chemical Co., Ltd. | Production process of cephem compound |
| TW526202B (en) * | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
| JP2003026679A (ja) * | 2001-07-10 | 2003-01-29 | Banyu Pharmaceut Co Ltd | 新規カルバペネム誘導体 |
| TW200305422A (en) * | 2002-03-18 | 2003-11-01 | Shionogi & Co | Broad spectrum cefem compounds |
| CA2504730C (en) | 2002-10-30 | 2011-04-12 | Astellas Pharma Inc. | Cephem compounds |
| JP2009530228A (ja) | 2006-03-16 | 2009-08-27 | アステラス製薬株式会社 | セフェム化合物および抗菌薬としての利用 |
| CN101343281A (zh) * | 2007-04-20 | 2009-01-14 | 山东轩竹医药科技有限公司 | 新型脒基吡啶基头孢菌素类化合物 |
| US9238657B2 (en) * | 2008-10-31 | 2016-01-19 | Shionogi & Co., Ltd. | Cephalosporin having catechol group |
| KR20130018845A (ko) * | 2010-04-05 | 2013-02-25 | 시오노기세야쿠 가부시키가이샤 | 카테콜기를 갖는 세펨 화합물 |
| CN102918047A (zh) | 2010-04-05 | 2013-02-06 | 盐野义制药株式会社 | 具有假儿茶酚基团的头孢烯类化合物 |
| US9085589B2 (en) * | 2010-04-28 | 2015-07-21 | Shionogi & Co., Ltd. | Cephem derivative |
| EP2590978B1 (en) * | 2010-06-18 | 2017-09-20 | FOB Synthesis, Inc. | Carbapenem antibacterials with gram-negative activity |
| KR101719556B1 (ko) | 2011-03-30 | 2017-03-24 | 주식회사 레고켐 바이오사이언스 | 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물 |
| US9334289B2 (en) * | 2011-04-28 | 2016-05-10 | Shionogi & Co., Ltd. | Cephem compound having catechol or pseudo-catechol structure |
| JP2013012630A (ja) | 2011-06-30 | 2013-01-17 | Toyota Industries Corp | 熱電変換モジュール |
| TWI547496B (zh) | 2011-10-04 | 2016-09-01 | 葛蘭素集團公司 | 抗菌化合物 |
| WO2013051597A1 (ja) | 2011-10-04 | 2013-04-11 | 塩野義製薬株式会社 | カテコール基を有するセフェム誘導体 |
| US8809314B1 (en) * | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
| UY35103A (es) * | 2012-10-29 | 2014-05-30 | Glaxo Group Ltd | Compuestos de cefem 2-sustituidos |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
| JPWO2014104148A1 (ja) * | 2012-12-26 | 2017-01-12 | 塩野義製薬株式会社 | セフェム化合物 |
| WO2017096472A1 (en) | 2015-12-10 | 2017-06-15 | Naeja-Rgm Pharmaceuticals Inc. | Cephem compounds, their production and use |
-
2016
- 2016-12-05 WO PCT/CA2016/051428 patent/WO2017096472A1/en not_active Ceased
- 2016-12-05 HK HK18113349.1A patent/HK1254209A1/zh unknown
- 2016-12-05 AU AU2016367284A patent/AU2016367284C1/en not_active Ceased
- 2016-12-05 BR BR112018009725A patent/BR112018009725A8/pt not_active IP Right Cessation
- 2016-12-05 KR KR1020197010752A patent/KR102135230B1/ko not_active Expired - Fee Related
- 2016-12-05 CA CA3005779A patent/CA3005779C/en active Active
- 2016-12-05 JP JP2018529261A patent/JP6967000B2/ja active Active
- 2016-12-05 KR KR1020187015784A patent/KR20180066264A/ko not_active Ceased
- 2016-12-05 CN CN201680072172.7A patent/CN108463461B/zh not_active Expired - Fee Related
- 2016-12-05 US US15/369,181 patent/US9751894B2/en not_active Ceased
- 2016-12-05 EP EP16871861.7A patent/EP3386977A4/en active Pending
- 2016-12-05 EA EA201891381A patent/EA039648B1/ru unknown
-
2018
- 2018-04-20 ZA ZA2018/02654A patent/ZA201802654B/en unknown
- 2018-05-09 IL IL259234A patent/IL259234B/en active IP Right Grant
- 2018-12-19 US US16/225,892 patent/USRE48097E1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6967000B2 (ja) | 2021-11-17 |
| USRE48097E1 (en) | 2020-07-14 |
| JP2018536678A (ja) | 2018-12-13 |
| US9751894B2 (en) | 2017-09-05 |
| US20170166587A1 (en) | 2017-06-15 |
| AU2016367284A1 (en) | 2018-05-10 |
| KR20190042752A (ko) | 2019-04-24 |
| HK1254209A1 (zh) | 2019-07-12 |
| EA039648B1 (ru) | 2022-02-21 |
| AU2016367284B2 (en) | 2018-05-17 |
| BR112018009725A2 (en) | 2018-11-06 |
| CN108463461A (zh) | 2018-08-28 |
| EA201891381A1 (ru) | 2019-01-31 |
| IL259234B (en) | 2018-12-31 |
| WO2017096472A1 (en) | 2017-06-15 |
| KR102135230B1 (ko) | 2020-07-17 |
| AU2016367284C1 (en) | 2018-09-20 |
| EP3386977A4 (en) | 2019-05-22 |
| KR20180066264A (ko) | 2018-06-18 |
| ZA201802654B (en) | 2019-07-31 |
| CA3005779A1 (en) | 2017-06-15 |
| CN108463461B (zh) | 2021-11-19 |
| EP3386977A1 (en) | 2018-10-17 |
| CA3005779C (en) | 2020-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018009725A8 (pt) | compostos de cefém, sua produção e uso | |
| CO2020007244A2 (es) | Inhibidores de kras g12c | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| CU20180073A7 (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2017003205A1 (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| BR112018075284A2 (pt) | derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os | |
| SI3790877T1 (sl) | Tetrahidro-imidazo(4,5-c)piridinski derivati kot imunomodulatorji pd-l1 | |
| EA201591506A1 (ru) | Гетероциклические амины в качестве ингибиторов киназы | |
| LT3442980T (lt) | Heterocikliniai junginiai, kaip ret kinazės inhibitoriai | |
| DK3555070T3 (da) | Aminsubstituerede, heterocykliske forbindelser som ehmt2-hæmmere og fremgangsmåder til anvendelse deraf | |
| LT3464272T (lt) | Nauji heterocikliniai dariniai, naudingi kaip shp2 inhibitoriai | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| UY35434A (es) | ?4-amino-6-(heterocíclico)picolinatos y 6-amino-2-(heterocíclico)pirimidin-4-carboxilatos y su uso como herbicidas?. | |
| MD3313851T2 (ro) | Noi derivați hidroxiester, procedeu pentru prepararea lor și compoziții farmaceutice care îi conțin | |
| BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| BR112016022046A2 (pt) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| CR20180564A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
| UA122773C2 (uk) | Спосіб одержання (4s)-4-(4-ціано-2-метоксифеніл)-5-етокси-2,8-диметил-1,4-дигідро-1,6-нафтиридин-3-карбоксаміду і його очищення для застосування як фармацевтичного активного інгредієнта | |
| CL2015003569A1 (es) | “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct | |
| BR112015029182A2 (pt) | composto para uso em modulação da rota wnt, uso do composto, método, composição farmacêutica, forma anidra, uso de uma base livre anidra | |
| DK3345900T3 (da) | 2,4-bis-(nitrogenholdig gruppe)-substitueret pyrimidinforbindelse samt fremgangsmåde til fremstilling og anvendelse deraf | |
| CL2016000726A1 (es) | Derivados de 4-azaindol | |
| DK3464260T3 (da) | Forbindelser, der indeholder ureamotiver, og derivater deraf som antibakterielle lægemidler | |
| BR112018016196A2 (pt) | derivados do dióxido de iminotiadiazinano como inibidores da plasmepsina v |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |